# Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

> **NCT00124215** · PHASE1 · COMPLETED · sponsor: **GlobeImmune** · enrollment: 48 (estimated)

## Conditions studied

- Hepatitis C

## Interventions

- **BIOLOGICAL:** GI-5005

## Key facts

- **NCT ID:** NCT00124215
- **Lead sponsor:** GlobeImmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-06
- **Final completion:** 2010-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2010-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124215, "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00124215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*